Author Archives: admin


Stem Cell Clinic > Articles by: admin

What’s Causing Your Hair Loss And The Secrets To Stopping IT – Harper’s Bazaar Singapore

By Stem Cell Treatment

Credit: 123RF

Its perfectly normal to lose up to 100 strands of hair a day. But how do you know if your hair is actually thinning or if youre just losing a little more than usual? And more importantly, what are the causes of hair loss and what can you do to manage it?

Here are five reasons youre losing hair and some solutions, from ways to destress and what food to eat for healthier hair, to an anti-hair loss treatment that uses stem cells.

Why you're losing your hair: Your hairstyle

We get it, the weather is hot and your hair is often tied back in a ponytail or in a bun. While its great to get your hair off your face, it could be the reason why youre losing hair. Constantly securing your locks in a tight and sleek hairstyle can not only damage hair, but also cause breakage. It also makes any hair loss around the crown and temples appear more noticeable.

What you can do: Try not to tie your hair up as often. Instead of knotting it into a tight bun or high ponytail, clip the sides back, just behind the ears, with this seasons trending barrettes.

Why you're losing your hair: You went on an extreme diet plan

Intermittent fasting might be all the rage now, but overdoing it and not feeding your body enough nutrients can result in thinning hair, and eventually, hair loss. Trust us, we know because weve seen it happen.

When you restrict your body from getting the nutrients it needs, the limited amount of energy it gets is diverted to the organs that need it most, like your heart, lungs and brain. This means that your hair, which also needs energy to grow, gets whats left or none at all.

What you can do:Load up on foods rich in iron, protein, omega 3-fatty acids and B vitamins, such as eggs, and green leafy vegetables like spinach and salmon. So even if you love what your new trendy diet has done for your weight, you shouldnt exclude these foods.

Why you're losing your hair: Your genetics

If youre eating and managing your stress well, yet are still shedding an alarming amount of hair daily, its time to visit the professionals. Apart from certain medical conditions that can cause hair loss, your genes can also play a part in early onset hair loss.

What you can do: One way is to head to a trichologist such as PHS Hairscience. The brand (together with bio-scientists and trichologists) has developed a Miracle Stem Cell Solution treatment, which uses a high concentration of stem cell proteins and a cocktail of active ingredients think nano-sized growth factors, peptides, cytokines, vitamins, antioxidants and DHT blockers (DHT is a hormone known to shrink the hair follicles, which can trigger the onset of hair loss).

When applied to the scalp, the stem cell proteins send signals to the hair follicles, to encourage the inactive cells to wake up and work harder.

At the same time, the other active ingredients nourish the scalp, helping it to become healthier. In fact, an independent laboratory study has shown that this Miracle Stem Cell Solution can help boost hairs growth cycle by up to 50 per cent!

The non-invasive hair treatment takes just 45 minutes per session and comes with no side effects or downtime. For best results, PHS Hairscience recommends that you go for bi-weekly sessions over three months, and results are said to be visible in as early as two months.

Its suitable for both women and men, and is available in five options to address the different types of hair loss: Hair Thinning Control, Hair Loss Control, Patchy Hair Loss Control, Hair Thickening Regenerator and Hair Growth Regenerator.

Why you're losing your hair: You have a crazy, stressful life

This current Covid-19 pandemic has put so much stress on everyone. Increased work and family stress can cause our bodies to produce more cortisol, commonly known as the stress hormone. Studies have shown that too much cortisol can disrupt the function and patterns of your hair growth cycle, which can contribute to increased shedding.

What you can do:Find ways to destress, like going out for a run, learning yoga or meditating before bed. The good news is that hair loss from stress is temporary, and once your levels are back to normal, the problem should go away.

Why you're losing your hair: You don't care for your scalp

Healthy hair begins with a healthy scalp. After all, your scalp is an extension of the skin on the face, so you should pay the same attention to the scalp too. Using products that are too drying can irritate the scalp and weaken the hair roots. And not cleansing the scalp of styling product build-up can suffocate the hair follicles all of which can lead to hair loss.

What you can do: In the same way that you have a daily skincare routine, you should also have one for your scalp and hair. Go here to find the right set of products for your hair and scalp concerns, from hair thinning to soothing a dry and sensitive scalp, and more.

More:
What's Causing Your Hair Loss And The Secrets To Stopping IT - Harper's Bazaar Singapore

Justin Thomas heads to PGA Championship with swagger of a champion – FanSided

By Stem Cell Treatment

Jaylen Brown continues to blossom during NBA restart by Steven Kubitza

Clayton Kershaw marvels in his first start of 2020 season for Dodgers by John Buhler

Justin Thomas (Photo by Andy Lyons/Getty Images)

Justin Thomas builds momentum for the PGA Championship by winning WGC in Memphis

A major champion is expected to excel under Sunday pressure, to pull off the right shot at the right time, and, of course, to get a little lucky at times. Justin Thomas is heading to the years first major championship next week after checking off all three boxes on Sunday in Memphis.

Thomas was bold, steady, and, at least for one hole, fortunate on his way to winning the WGC-FedEx St. Jude Invitational at TPC Southwind. He erased a four-shot deficit at the start of the round and ended up winning by three after a five-under 65 on Sunday. Its the 13th PGA Tour title of his still-young career, making the 27-year-old Thomas the third-youngest player in the last 60 years to reach that milestone behind Tiger Woods and Jack Nicklaus.

Hes also the first player this season to reach three victories and will take over the No. 1 spot on the Official World Golf Rankings for the first time since June 2018. Thomas is at the top of his game, and just in time too: the PGA Championship begins on Thursday at TPC Harding Park in San Francisco.

Thomas knows what it feels like to lift the Wanamaker Trophy, winning his lone major championship at Quail Hollow in 2017. But, before this week, he didnt look like a player with the confidence to win another one. Thomas has been in contention twice since the PGA Tour resumed in June. Entering the final round of the Charles Schwab Challenge at Colonial a shot off the lead, he made only two birdies on Sunday and slipped to 10th. Again, last month at the Workday Charity Open, he had a three-shot lead over Collin Morikawa with three holes remaining. He finished bogey-par-bogey before losing in a playoff.

It was those crushing defeats, and the lessons he learned from them, that he admits helped him win this week. It means a lot, especially with how I felt that I did it, he told CBS after completing his round. In the past Ive struggled coming from behind. I learned from it at Colonial. I felt like I got really wrapped up in what was going on on the leaderboard, who was ahead of me, how many people, instead of just focusing on my own game.

(Today) I didnt look at a leaderboard until I accidentally starred at one on 13 tee. And then again at Workday, I learned from that. It sucked. Im going to be mad about that for the rest of my life. But its because of days like that is why I felt like I was able to hold on and get it done today.

Thomas trailed leader Brendon Todd by four shots at the beginning of the day; he completely made up that deficit on the front-nine, rolling in a 20-foot birdie putt at the ninth to take a share of the lead. But then he found trouble at the 12th, his approach shot taking a bad hop off the mound to the left green and nestling in under the lip of a bunker. Rather than attempt a risky, miraculous shot, Thomas made the smart play and chipped out into the rough, settling for a well-earned bogey.

Then came at the 15th hole, where Thomas got a break that may have won him the tournament. His drive on the par-four looked like it was heading well left into an area thick with trees. The ball couldve deflected off any of them and went anywhere. Instead, it went right through the trees and left him just 50 yards to the hole for his second shot. It was the type of luck that seemingly only comes to the winner of a tournament.

I got unbelievably lucky, Thomas admits. But thats the stuff that happens when you win, it really is. Somehow, that kind of calmed me down. You know, when that happened I was like this could be for us. Stuff like that doesnt happen more often than not unless you win the tournament.

The lone challenger to Thomas lead by the end of the round was another former PGA winner, the two-time defending champ Brooks Koepka. Koepka has shown throughout his career he brings his best game to the biggest tournaments; he has seven career wins on the PGA Tour, four of them majors. So, predictably with a major a few days away, Koepka was in contention for his first title since winning this same tournament last year. His run, though, ended when his tee shot at the 18th wound up in the water hazard, sending him into a four-way tie for second at 10-under, three behind Thomas.

Koepka has been dealing with a left knee injury since last fall. He underwent stem cell treatment in September, but that hasnt alleviated the problem. He admitted before the tournament this week that he still cant run and can barely ride a bike. The injury has affected his play on the course; in his last three events, he missed two cuts and finished tied for 62nd.

But a missed cut last week at the 3M Open in Minnesota allowed him to spend more time with his coach Pete Cowen, who he hadnt seen since March, and a new putting coach, Phil Kenyon. The results were immediate; he set a new career-best with a 62 on Thursday.

Thomas and Koepka are peaking at just the right time. The next seven weeks on the PGA Tour will feature the PGA Championship, the FedEx Cup playoffs, and the U.S. Open. Its the types of events both excel in. And now theyre both heading to San Francisco with a little extra bit of confidence.

But its Thomas whos going with a trophy in tow, as well as the top spot in the rankings and a new title: the favorite to win his second Wanamaker Trophy.

More here:
Justin Thomas heads to PGA Championship with swagger of a champion - FanSided

stem cell doctor – regenexx.com

By Stem Cell Doctors

This past year or so I have lectured at many conferences and taught a few courses on the orthopedic use of stem cells. What I have seen and experienced concerns me greatly. With the explosion in stem cell use this past year, the number of people doing it well has become a smaller and smaller percentage of the total physicians offering the treatment.

First, why is this happening? The race by physicians to adopt stem cells has created a weird educational problem. Physicians that have full practices dont have a lot of time for education and the companies that sell automated centrifuges or kits to concentrate stem cells have financial incentives to sell as many as possible. Put these together and you get what we see doctors who dont have the base training to do this type of work, who arepoorly trained.

I can break these stem cell doctors down into a few different categories:

1. I have no clue how to use guidance-These physicians include many orthopedic surgeons and family doctors. For example, they know that injecting stem cells into the knee joint accurately is important, but they refuse to use imaging guidance to ensure theyre in the joint. For some, like many orthopedic surgeons its arrogance. They believe thatdespite scientific studies to the contrary, they can accurately access the joint. Other times, its just unwillingness to climb the steep educational mountain of learning ultrasound or fluoroscopy and purchase expensive new equipment.

2. I took a weekend course so now I can advertise that Im a stem cell expert-There is a saying, dont know what they dont know that accurately describes this group. Simple but critical details have been left out of their training. For example, the fact that certain common anesthetics will kill stem cells dead. Or that taking stem cells from only one bone marrow site virtually assures that the total number of stem cells will be less than when multiple sites are drawn.

3. This is a heck of a business opportunity-This group is made up of physicians who are more businessmen than doctors. Theysimply dont care if these procedures are being done right or wrong, only that the public sees a slick web-site and anyone who has a credit card is a candidate. They see dollar signs and anything that reduces the bottom line (like extensive training) isnt a good thing.

4. I have no idea what Im injecting, but some sales rep told me it was stem cells-These doctors have very little knowledge about stem cells and unlike the doctors above, wont be bothered to have to buy new equipment or take a course. They simply want something that sits on the shelf that they can inject when somebody with the cash comes by that wants a stem cell injection. In this case an attractive sales rep came to the office and told them that an expensive little vial contained amniotic stem cells. They took the bait hook, line, and sinker never questioning as we did whether what the sales rep claimed was accurate or simply just a tale told to sell product. Regrettably the vial of amniotic stem cells sitting in the freezer doesnt contain any living cells, let alone stem cells.

5. I only kind of know what Im injecting-These clinics tend to use bedside centrifuges and have no ability to count the dose of whats being injected, hence they really have no idea if the stem cell draw was adequate or if they have many or few cells. All this is obviously critical for delivering high quality care.

6. I only kinda know where Im injecting-These doctors use guidance (unlike the category described as #1 above), but they only use it at the most basic level of competency. So for example, if your ACL ligament in the knee needs stem cells, they would have no idea how to get stem cells to that specific spot, simply how to generally get them inside the knee joint which wont help your ACL much.

What can you do as a patient to protect yourself as a patient considering orthopedic stem cell therapies? Here are questions to ask your doctor:

1. Do you use imaging guidance to take, and place, cells? If no, then find a provider that does.

2. How many hours of stem cell specific training have you had? How many patients have you treated with stem cells? Be a bit careful here, as the staff wont know the answer to these questions and the doctor will often give evasive answers. In addition, many doctors will often substitute their experience with platelet rich plasma when they answer the stem cell experience question to make it look like they have more experience than they actually have.

3. Be wary of any clinic that claims they areinjecting amniotic stem cells. There is no commercial product that we have tested that contains any viable stem cells and if the doctor is claiming or suggesting that he or she is doing this their knowledge of stem cells only extends to what thesales rep told them to push product never a good thing.

4. Ask if the doctor has the ability to count the cells that come out of his machine. Ask to see those exact counts. If they cant do this run

5. Make sure that the stem cell doctor has advanced interventional skills i.e. has the ability to precisely place the cells where theyre needed. Heres a question to ask -How many different structures in the knee can your doctor inject under guidance and can you name them?. The answer for a high level and sophisticated provider would be: intra-articular, patellar and quadriceps tendons, patello-femoral joints, ACL, PCL, MCL, LCL, pes anserine tendons, medial meniscus, lateral meniscus, etc If what you hear is that the doctor puts them inside the knee and they know where to go, run

The upshot? At Regenexx we hand pick doctors who have certain skills and this makes them a 1 in 100 doctor . We then train and support these doctors extensively. The good news for our patients is that they can access physicians all over the country that are highly skilled, the bad news for the average patient who doesnt do his or her homework is that the likelihood of randomly finding one of those highly skilled doctors is getting lower and lower every year!

Read more:
stem cell doctor - regenexx.com

How Airway Cells Work Together in Regeneration and Aging – Technology Networks

By Stell Cell Research

Microscopic image showing stem cells in young (left) and old (right) airways with cell nuclei seen in blue, airway basal stem cells seen in red and ciliated cells seen in green. Credit: Broad Stem Cell Research Center

Read Time:

Researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have identified the process by which stem cells in the airways of the lungs switch between two distinct phases -- creating more of themselves and producing mature airway cells -- to regenerate lung tissue after an injury.

The study, published in Cell Stem Cell, also sheds light on how aging can cause lung regeneration to go awry, which can lead to lung cancer and other diseases.

"There currently are few therapies that target the biology of lung diseases," said Dr. Brigitte Gomperts, a professor and vice chair of research in pediatric hematology-oncology at the UCLA Children's Discovery and Innovation Institute and the paper's senior author. "These findings will inform our efforts to develop a targeted therapy to improve airway health."

The airways, which carry the air that is breathed in from the nose and mouth to the lungs, are the body's first line of defense against airborne particles -- like germs and pollution -- that can cause illness.

Two types of airway cells play a vital role in this process: mucus cells, which secrete mucus to trap harmful particles, and ciliated cells, which use their finger-like projections to sweep the mucus-engulfed particles up to the back of the throat, where they can be cleared out of the lungs.

The infectious or toxic particles that people breathe in every day can injure the airways and when that happens, airway basal stem cells -- which are capable of self-renewing and producing the mucus and ciliated cells that line the airways -- activate to repair the damage.

To keep the right balance of each cell type, airway basal stem cells must transition from the proliferative phase, during which they produce more of themselves, to the differentiation phase, during which they give rise to mature airway cells.

"These stem cells have to maintain a really delicate equilibrium," said Gomperts, who is also co-director of the cancer and stem cell biology program at the UCLA Jonsson Comprehensive Cancer Center. "They have to produce just the right amount of mucus and ciliated cells to keep harmful particles out of the lungs, but they also have to self-replicate to ensure there will be enough stem cells to respond to the next injury."

In the new study, the researchers examined mice with lung injuries, analyzing how the different types of cells found in the niche -- the supportive environment that surrounds airway basal stem cells -- work together to orchestrate the repair response.

They found that a group of molecules known as the Wnt/beta-catenin signaling pathway activates to stimulate the airway basal stem cells to respond to injury. The researchers were surprised to discover that this group of molecules originates in one cell type to initiate proliferation and another cell type to initiate differentiation.

In the proliferation phase of repair, a connective tissue cell called a fibroblast secretes the Wnt molecule, which signals to the stem cells that it's time to self-renew. In the differentiation phase of repair, the Wnt molecule is secreted by an epithelial cell, which make up the lining of tissues and organs, to signal to the stem cells that it's time to produce mature airway cells.

Understanding how regeneration occurs in healthy lungs is a critical first step to understanding how disease can arise when the process goes wrong. Seeking insights into what role this process and the cells that activate it might play in disease, the scientists studied its activity in older mice.

"We were surprised to find that in the aging airways, the Wnt/beta-catenin signaling pathway is active in the stem cells even when there is no injury, in contrast to the young airways where it is only activated when necessary," said Cody Aros, the paper's first author, a UCLA medical student who recently completed his doctoral research. "When this pathway is active, it stimulates the stem cells to produce more of themselves and more airway cells -- even if they're not needed."

Previous research by Gomperts' lab has established a link between a more active Wnt/beta-catenin pathway and lung cancer.

"The more a cell divides, the more likely it is that a proofreading error or mutation can occur and lead to cancer," Gomperts said.

The new paper builds on that work by establishing not just what goes wrong but precisely when it goes wrong in otherwise healthy people as part of the aging process.

"These findings give us insight into which cell types are important, which pathway is important and when we might want to think about intervening with therapies to prevent the formation of cancer," Aros said.

Reference:Aros, C. J., Vijayaraj, P., Pantoja, C. J., Bisht, B., Meneses, L. K., Sandlin, J. M., . . . Gomperts, B. N. (2020). Distinct Spatiotemporally Dynamic Wnt-Secreting Niches Regulate Proximal Airway Regeneration and Aging. Cell Stem Cell. doi:10.1016/j.stem.2020.06.019

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Visit link:
How Airway Cells Work Together in Regeneration and Aging - Technology Networks

T-Cell Lymphoma Market 2020 | Research Objectives and Methodology, Growth Analysis, Top Manufacturers Sales, and Cost Structures Forecast 2024 – Owned

By Stem Cell Treatment

Spectrum Pharmaceuticals

Report Highlights:

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/14244452

Key Market Trends:

Chemotherapy is Expected to Hold Significant Market Share in the Type of Therapy

There are a variety of treatment options available for the treatment of T-cell lymphoma and leukaemia. While surgery and radiation therapy are used to remove or kill cancer cells in a particular area, chemotherapy can act on the rapidly dividing cancer cells throughout the entire body. With intensive chemotherapy, the complete remission rate can be very high, and many patients can be cured. Chemotherapy for the treatment of T-cell lymphoma or leukaemia may be delivered in several ways, such as intravenous, oral, and intrathecal.

North America Dominates the Market and is Expected to do Same during the Forecast Period

According to the Lymphoma Research Foundation, T-cell lymphomas account for about 7% of all non-Hodgkins lymphoma (NHL) in the United States, according to their Surveillance, Epidemiology, and End Results program. In addition, Angioimmunoblastic T-Cell Lymphoma (AITL) is a rare, aggressive type, accounting for about 7-8% of all patients having T-cell lymphomas in the United States. Most patients have been found to be middle-aged to elderly, and are diagnosed with advanced stage disease. Several organizations are currently playing a significant role in spreading awareness regarding T-cell Lymphoma across the region. For example, the Leukemia and Lymphoma Society (LLS) is the worlds largest voluntary health organization dedicated to funding blood cancer research, education and patient services. LLS has chapters throughout the United States, and in Canada. Moreover, despite an overall decline observed for non-Hodgkin lymphoma incidence, the incidence of T-cell lymphomas continues to rise. Therefore, due to these rising incidences in the United States, the T-cell lymphoma market is expected to grow during the forecast period.

The Report Covers:

Purchase this Report (Price 4250 USD for single user license) https://www.industryresearch.co/purchase/14244452

Detailed TOC of T-Cell Lymphoma Market Report 2020-2024:

1 INTRODUCTION 1.1 Study Deliverables 1.2 Study Assumptions 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.2.1 Rise in Lymphoma Cancer Incidence due to Radiations 4.2.2 Increase in Number of T-cell Lymphoma Specific Therapies 4.2.3 Risk of Lymphoma due to Autoimmune Disorders 4.3 Market Restraints 4.3.1 High Cost of Treatment 4.3.2 Adverse Side Effects of Therapies 4.4 Porters Five Forces Analysis 4.4.1 Threat of New Entrants 4.4.2 Bargaining Power of Buyers/Consumers 4.4.3 Bargaining Power of Suppliers 4.4.4 Threat of Substitute Products 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION 5.1 Type of Lymphoma 5.1.1 Peripheral T-cell Lymphoma 5.1.2 Cutaneous T-cell Lymphoma 5.1.3 Anaplastic Large Cell Lymphoma 5.1.4 Angio-immuno-blastic T-cell Lymphoma 5.1.5 Other Types of Lymphoma 5.2 Type of Therapy 5.2.1 Radiotherapy 5.2.2 Chemotherapy 5.2.3 Surgery and Stem Cell Transplantation 5.3 Geography 5.3.1 North America 5.3.1.1 United States 5.3.1.2 Canada 5.3.1.3 Mexico 5.3.2 Europe 5.3.2.1 Germany 5.3.2.2 United Kingdom 5.3.2.3 France 5.3.2.4 Italy 5.3.2.5 Spain 5.3.2.6 Rest of Europe 5.3.3 Asia-Pacific 5.3.3.1 China 5.3.3.2 Japan 5.3.3.3 India 5.3.3.4 Australia 5.3.3.5 South korea 5.3.3.6 Rest of Asia-Pacific 5.3.4 Middle East & Africa 5.3.4.1 GCC 5.3.4.2 South Africa 5.3.4.3 Rest of Middle East & Africa 5.3.5 South America 5.3.5.1 Brazil 5.3.5.2 Argentina 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE 6.1 Company Profiles 6.1.1 Biocryst Pharmaceuticals Inc. 6.1.2 Bristol-Myers Squibb 6.1.3 Genmab AS 6.1.4 Johnson & Johnson 6.1.5 Merck & Co. Inc. 6.1.6 Novartis 6.1.7 Roche Holding 6.1.8 Shionogi & Company Limited 6.1.9 Spectrum Pharmaceuticals

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Household Gas Stoves Market 2020 Global Size Estimation by Demand Status, Business Outlook, Growth Opportunities, Future Trends, Key Drivers, Forecast to 2026 Research by Industry Research.co

Soft Drinks Packaging Market 2020 Major Drivers, Global Industry Insights by Global Players, Regional Segmentation, Growth, Applications, Value and Forecasts till 2025

Aerospace Industry Semi-Finished Honeycomb Materials Market Growth, Industry Trends 2020 Size by Regions, Global Industry Share, Sales Revenue and Opportunities till 2026 with COVID-19 Impact

Diesel Generator Belt Market Growth, Industry Trends 2020 Size by Regions, Global Industry Share, Sales Revenue and Opportunities till 2026 with COVID-19 Impact

Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheters Market Growth, Industry Trends 2020 Size by Regions, Global Industry Share, Sales Revenue and Opportunities till 2026 with COVID-19 Impact

Builders Joinery and Carpentry Of Wood Market Size Report 2020: Global Industry Analysis by Trends, Revenue, Share, Revenue and COVID-19 Impact Forecast to 2024

See the article here:
T-Cell Lymphoma Market 2020 | Research Objectives and Methodology, Growth Analysis, Top Manufacturers Sales, and Cost Structures Forecast 2024 - Owned

BioMarin (BMRN) to Report Q2 Earnings: What’s in the Cards? – Zacks.com

By Gene Therapy Clinics

BioMarin Pharmaceutical (BMRN - Free Report) is set to report second-quarter 2020 results on Aug 4, after market close. In the last reported quarter, the company delivered an earnings surprise of 90.91%.

BioMarins shares have risen 43.9% this year so far, outperforming the industrys increase of 5%.

The companys earnings performance has been mixed. Its earnings beat expectations in three of the last four quarters and missed in one, with the surprise being 22.34%, on average.

The negative impact of disruptions of day-to-day operations of clinics and hospitals is expected to have been more acute in the second quarter than the first. The pandemic is expected to have caused demand interruptions such as missed patient infusions and disruption in new patient starts of some of BioMarins drugs in the second quarter.

Sales of Kuvan are likely to have been driven by patient growth in North America. However, Naglazyme and Vimzim revenues vary on a quarterly basis, primarily due to the timing of central government orders from some countries, mainly Brazil. Sales of both the drugs had increased in the first quarter. It remains to be seen if the trend has reversed in the second quarter. The respective Zacks Consensus Estimate for Kuvan, Naglazyme and Vimzim is $114 million, $86 million and $119 million.

In new medicine, Palynziq injection, a seasonal slowing of new patient enrollments and patient starts had hurt sales in the first quarter. It remains to be seen if the trend reversed in the second quarter. The Zacks Consensus Estimate for Palynziq is $35.4 million.

We expect management to provide a thorough update on its pipeline. BioMarins regulatory applications for Roctavian/valoctocogene roxaparvovec (valrox), a gene therapy for severe hemophilia A, are under review in the United States (PDUFA Date: Aug 21) and Europe with potential approval and launch in the United States in the second half of 2020.

Another important candidate in its pipeline is vosoritide, which has been developed to treat achondroplasia, the most common form of dwarfism. The company filed a regulatory application for vosoritide in the EU in July and expects to file the same in the United States in the third quarter of 2020.

Meanwhile, investors will also look for any changes to its financial guidance for 2020 on the second-quarter conference call.

Our proven model does not conclusively predict an earnings beat for BioMarin this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here.

Earnings ESP: Its Earnings ESP is 0.00% as both the Zacks Consensus Estimate as well as the Most Accurate Estimate is pegged at 16 cents per share. You can uncover the best stocks to buy or sell before theyre reported with our Earnings ESP Filter.

Zacks Rank: BioMarin currently carries a Zacks Rank #1.

Here are two biotech stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat in their upcoming release.

Incyte Corporation (INCY - Free Report) has an Earnings ESP of +4.62% and a Zacks Rank #3.

Arena Pharmaceuticals. (ARNA - Free Report) has an Earnings ESP of +12.88% and a Zacks Rank #3.

bluebird bio (BLUE - Free Report) has an Earnings ESP of +69.18% and a Zacks Rank #3.

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>

See the original post here:
BioMarin (BMRN) to Report Q2 Earnings: What's in the Cards? - Zacks.com

Stem Cell Characterization Kits Market Research Report and Outlook by 2018 to 2026 – Owned

By Stell Cell Research

Fact.MR, in a recently published report, offers valuable insights related to the key factors that are projected to influence the growth of the Stem Cell Characterization Kits market during the forecast period, 2019-2029. The current market trends, vast growth opportunities in different regional markets, market drivers, and restraining factors are thoroughly analyzed in the report on the Stem Cell Characterization Kits market.

The data enclosed in the report such as the Year-on-Year (Y-o-Y) market growth, supply chain analysis, value chain analysis and more will enable readers to assess the quantitative aspects of the Stem Cell Characterization Kits market with clarity. The presented study is a vital asset for stakeholders, investors, and market players involved in the Stem Cell Characterization Kits market who can leverage the information in the report to develop effective business strategies.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=2691

Key Findings of the Report:

Stem Cell Characterization Kits Market Segmentation

The report on the Stem Cell Characterization Kits market provides vital analytical insights related to the key market segments including, region, application, and end-use. Further, the report discusses the current and future prospects of each market segment along with informative graphs, tables, and figures.

Segments of the Stem Cell Characterization Kits market assessed in the report:

Competitive landscape

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=2691

Important Queries Related to the Stem Cell Characterization Kits Market Addressed in the Report:

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=2691

Reasons to Buy From Fact.MR

See the article here:
Stem Cell Characterization Kits Market Research Report and Outlook by 2018 to 2026 - Owned

Cell Expansion Market Set to Surpass US$XX Million by the end of 2017 2025 – Owned

By Stell Cell Research

Evaluation of the Global Cell Expansion Market

The presented study maps the growth trajectory of the global Cell Expansion market by thoroughly assessing the various factors that are expected to influence the future prospects of the Cell Expansion market. According to the report published by PMR, the Cell Expansion market is poised to attain a value of ~US$ XX Mn/Bn by the end of 2029 with a CAGR growth of ~XX% during the forecast period (2019-2029).

A complete evaluation of the trends, market drivers, opportunities, and challenges faced by market players operating in the Cell Expansion market is provided in the report. Further, an overview and introduction of the Cell Expansion market is included to ensure that the readers have a seamless experience while going through the contents of the report.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/15757

Critical insights included in the report:

Competitive Outlook

The competitive outlook assessment provides an in-depth understanding related to the business proceeding of top-tier market players in the global Cell Expansion market. The product portfolio, sales strategy, marketing & promotional strategy, and sales footprint of each market player is scrutinized thoroughly in the report. Some of the leading players evaluated in the report include:

The report segments the global Cell Expansion market on the basis of region, product type, and end use.

Key Players

The major players in cell expansion market include Beckman Coulter, Inc, Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Terumo BCT, Inc., Corning, Inc., Stemcell Technologies, Inc., GE Healthcare, Merck KGaA (Sigma-Aldrich Co. LLC), Lonza, Miltenyi Biotec among others. Companies have several ongoing research for cell-based therapies and stem cell-based therapies; it has been found that companies are in the development of new products and systems which ensure market growth during the forecast period. Only a few manufacturing companies are involved in the manufacturing of cell expansion instruments.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/15757

Regional Analysis

The market scenario in each region along with a comprehensive assessment of the micro and macro-economic factors that are forecasted to impact the market growth in these regions is included in the report.

End Use Assessment

The market study offers accurate and in-depth analysis of the various end uses of the Cell Expansion along with a yearly comparison of the market share and revenue growth of each end use.

Important queries addressed in the report:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/15757

Why Opt for PMR?

Continue reading here:
Cell Expansion Market Set to Surpass US$XX Million by the end of 2017 2025 - Owned

Regenerative Medicine Products to Discern Magnified Growth During 2019-2025 – Owned

By Stem Cell Medicine

Analysis of the Global Regenerative Medicine Products Market

The presented global Regenerative Medicine Products market report provides reliable and credible insights related to the various segments and sub-segments of the market. The market study throws light on the various factors that are projected to impact the overall dynamics of the global Regenerative Medicine Products market over the forecast period (20XX-20XX).

According to the report, the value of the Regenerative Medicine Products market was estimated to reach ~US$ XX in 2019 and attain a market value of ~US$ XX by the end of 2029. Further, the study reveals that the market is set to grow at a CAGR of XX% during the forecast period owing to a plethora of factors.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2630513&source=atm

The market study aims to provide answers to the following questions related to the Regenerative Medicine Products market:

The report splits the global Regenerative Medicine Products market into different market segments such as:

The region-wise segmentation offers critical information such as the market share, size, revenue analysis, growth prospects, and market attractiveness of each region.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2630513&source=atm

Market Segment Analysis The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type, the Regenerative Medicine Products market is segmented into Cell Therapy Tissue Engineering Biomaterial Others

Segment by Application Dermatology Cardiovascular CNS Orthopedic Others

Global Regenerative Medicine Products Market: Regional Analysis The Regenerative Medicine Products market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026. The key regions covered in the Regenerative Medicine Products market report are: North America U.S. Canada Europe Germany France U.K. Italy Russia Asia-Pacific China Japan South Korea India Australia Taiwan Indonesia Thailand Malaysia Philippines Vietnam Latin America Mexico Brazil Argentina Middle East & Africa Turkey Saudi Arabia U.A.E Global Regenerative Medicine Products Market: Competitive Analysis This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019. The major players in global Regenerative Medicine Products market include: Acelity DePuy Synthes Medtronic ZimmerBiomet Stryker MiMedx Group Organogenesis UniQure Cellular Dynamics International Osiris Therapeutics Vcanbio Gamida Cell Golden Meditech Cytori Therapeutics Celgene Vericel Corporation Guanhao Biotech Mesoblast Stemcell Technologes Bellicum Pharmaceuticals

Vital data enclosed in the report:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2630513&licType=S&source=atm

Read the rest here:
Regenerative Medicine Products to Discern Magnified Growth During 2019-2025 - Owned

Induced Pluripotent Stem Cells (iPSCs) Market Application And Specification, Product Category, Downstream Buyers,Top Player with Forecast till 2026 -…

By Induced Pluripotent Stem Cells

This Induced Pluripotent Stem Cells (iPSCs) Market report offers a detailed view of market opportunity by end user segments, product segments, sales channels, key countries, and import / export dynamics. It details market size & forecast, growth drivers, emerging trends, market opportunities, and investment risks in over various segments in Induced Pluripotent Stem Cells (iPSCs) industry. It provides a comprehensive understanding of Induced Pluripotent Stem Cells (iPSCs) market dynamics in both value and volume terms.

About Induced Pluripotent Stem Cells (iPSCs) Industry

The overviews, SWOT analysis and strategies of each vendor in the Induced Pluripotent Stem Cells (iPSCs) market provide understanding about the market forces and how those can be exploited to create future opportunities.

Important application areas of Induced Pluripotent Stem Cells (iPSCs) are also assessed on the basis of their performance. Market predictions along with the statistical nuances presented in the report render an insightful view of the Induced Pluripotent Stem Cells (iPSCs) market. The market study on Global Induced Pluripotent Stem Cells (iPSCs) Market 2018 report studies present as well as future aspects of the Induced Pluripotent Stem Cells (iPSCs) Market primarily based upon factors on which the companies participate in the market growth, key trends and segmentation analysis.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2647159&source=atm

Regional and Country-level Analysis The report offers an exhaustive geographical analysis of the global Induced Pluripotent Stem Cells (iPSCs) market, covering important regions, viz, North America, Europe, China, Japan and Brazil. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc. The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026. Competition Analysis In the competitive analysis section of the report, leading as well as prominent players of the global Induced Pluripotent Stem Cells (iPSCs) market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020. On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Induced Pluripotent Stem Cells (iPSCs) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Induced Pluripotent Stem Cells (iPSCs) market. The following players are covered in this report: Fujifilm Holding Corporation (CDI) Ncardia Sumitomo Dainippon Pharma Astellas Pharma Inc Fate Therapeutics, Inc Pluricell Biotech Cell Inspire Biotechnology ReproCELL Induced Pluripotent Stem Cells (iPSCs) Breakdown Data by Type Human iPSCs Mouse iPSCs Human iPSCs had a market share of 89.65% in 2019, followed by Mouse iPSCs. Induced Pluripotent Stem Cells (iPSCs) Breakdown Data by Application Academic Research Drug Development and Discovery Toxicity Screening Regenerative Medicine Others Academic Research is the largest segment of Induced Pluripotent Stem Cells (iPSCs) application,with a share of 32% in 2019.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2647159&source=atm

The scope of Induced Pluripotent Stem Cells (iPSCs) Market report:

Global market size, supply, demand, consumption, price, import, export, macroeconomic analysis, type and application segment information by region, including:

Global (Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]

Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]

North America [United States, Canada, Mexico]

Middle East & Africa [GCC, North Africa, South Africa],

South America [Brazil, Argentina, Columbia, Chile, Peru])

Industry chain analysis, raw material and end users information

Global key players information including SWOT analysis, companys financial figures, Laser Marking Machine figures of each company are covered.

Powerful market analysis tools used in the report include: Porters five forces analysis, PEST analysis, drivers and restraints, opportunities and threatens.

Based year in this report is 2019; the historical data is from 2014 to 2018 and forecast year is from 2020 to 2024.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2647159&licType=S&source=atm

Manufacturing Analysis Induced Pluripotent Stem Cells (iPSCs) Market

Manufacturing process for the Induced Pluripotent Stem Cells (iPSCs) is studied in this section. It includes through analysis of Key Raw Materials, Key Suppliers of Raw Materials, Price Trend of Key Raw Materials, cost of Raw Materials & Labor Cost, Manufacturing Process Analysis of Induced Pluripotent Stem Cells (iPSCs) market

Marketing Strategy Analysis, Distributors/Traders Analysis of Induced Pluripotent Stem Cells (iPSCs) Market

Various marketing channels like direct and indirect marketing are portrayed in Induced Pluripotent Stem Cells (iPSCs) market report. Important marketing strategical data , Marketing Channel Development Trend, , Pricing Strategy, Market Positioning, Target Client Brand Strategy and Distributors/Traders List

More:
Induced Pluripotent Stem Cells (iPSCs) Market Application And Specification, Product Category, Downstream Buyers,Top Player with Forecast till 2026 -...

→←